金属蛋白酶3、抗环瓜氨酸肽和类风湿因子分型对类风湿关节炎临床检测的应用被引量：1

金属蛋白酶3、抗环瓜氨酸肽和类风湿因子分型对类风湿关节炎临床检测的应用

导出

摘要目的:基质金属蛋白酶-3(MPP-3)、抗环瓜氨酸肽(CCP)抗体、类风湿因子分型(RF)检测对于类风湿关节炎(RA)患者疾病进程的临床预测价值。方法:采用ELISA检测法,测定血清MMP-3、抗CCP抗体、RF lgM、RF lgG、RF lgA的含量。结果:(1)MMP-3、抗CCP抗体及RF lgM、RF lgG、RF lgA在健康对照组均有显著性意义(P<0.01),抗CCP、RF在RA各组血清水平均高于非RA及对照组(P<0.01);MMP-3在RA组具有较高含量,显著高于非RA组、健康对照(P<0.01);在RA1组与RA2组中水平比较差别明显(P<0.01),在RA2组与RA3组中水平比较差别明显(P<0.01)。(2)RA组中MPP-3、抗CCP抗体、RF lgM+RF lgG+RF lgA的敏感度分别为65.3%,68.7%,71.8%。(3)MMP-3、抗CCP与RF lgM+RF lgG+RF lgA在RA组中特异性分别为70.2%,95.1%,83.1%。(4)五项指标的联合检测敏感度为32.8%,联合特异度为100%。结论:联合检测五项指标可降低RA的漏诊率。动态联合测定抗CCP抗体、RF lgM、RF lgG、RF lgA、MMP-3能更有效地及时监测RA的疾病进展,对指导临床诊治及干预有积极意义。 Objective： Matrix metalloproteinase - 3 （ MPP - 3 ）, anti - cyclic citrullinated peptide （CCP） antibodies, rheuma- toid factor scores （RF） detection of clinical predictive value for rheumatoid arthritis （RA） patients with disease progression. Method： Using quantitative ELISA serum MMP - 3, anti - CCP antibody RF lgM RF lgG, RF lgA. Results （ 1 ） MMP - 3, anti - CCP antibod- ies and RF lgM RF lgG, RF lgA in the healthy control group were significantly significance （P 〈 0. O1 ）, resistance to the CCP and RF in RA serum water were higher than those in non - RA and the control group （ P 〈 0. 01 ） ; MMP - 3 has a higher content in the RA group was significantly higher than the non - RA group and healthy controls （ P 〈 0. 01 ） ; RA1 RA2 group level comparison was signifi- cantly different （ P 〈 0. 01 ）, in comparison with the level of RA3 group RA2 group was significantly different （ P 〈 0.01 ）. （ 2 ） RA group MPP -3, anti -CCP antibodies, RF lgM ＋ RF lgG ＋ RF lgA sensitivity of 65.3%, 68. 7% and 71.8%, respectively. （3） MMP - 3 ; anti - CCP and RF lgM ＋ RF lgG ＋ RF lgA in the RA group specificity were 70. 2%, 95.1% , 83.1%. （4） The five in- dicators of joint detection sensitivity of 32. 8%, joint specificity of 100%. Conclusion ： Combined detection of five indicators to reduce the rate of misdiagnosis of RA. Dynamic joint determination of anti - CCP antibodies, RF lgM, RF lgG RF lgA of MMP - 3 can be more effective timely monitoring of disease progression in RA guiding clinical treatment and intervention.

作者杨秉潜

机构地区广东省梅州市人民医院

出处《中国民族民间医药》 2013年第12期29-30,共2页 Chinese Journal of Ethnomedicine and Ethnopharmacy

关键词类风湿关节炎基质金属蛋白酶-3 抗环瓜氨酸肽抗体类风湿因子分型 rheumatoid arthritis matrix metalloproteinase- 3 anti -cyclic citrullinated peptide antibody rheumatoidfactor typing

分类号 R593.22 [医药卫生—内科学]

引文网络
相关文献

参考文献10

1Peake NJ, Khawaja K, Myers A, et al. Levels of matrix meta Uoproteinuse (MMP) -1 in paired ser- 8 and synovial fuids of juvenile idiopathic arthritis patients: relationship to inflammatory activity, MMP- 3 and tissueinhibitor ofmetal- loproteinases - 1 in a longitudinal study [ J ]. Rheumatology, 2005, 44 ( 11 ) : 1383 - 1389.
2Markku H, Leila R, Jorma M, et al. Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis [ J ]. Ann Rheum Dis, 1993, 52 (4): 866-869.
3Atetaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: all American College of Rheumatology/European League Against Rheumatism collaborative initiative [J]. Ann Rheum Dis, 2010, 69 (9) : 1580 - 1583.
4Fiedorczyk M, Klimiuk PA, Sierakowski S, et al. Serum matrix metallopro- teinases and tissue inhibitors of matalloproteinases in patients with early rheumatoid arthritis [J]. Rheumatol, 2006, 33 (8): 1523-1529.
5Hisashi Y, Yuko M, Michi T, et al. Serum matrix metalloproteina - 3 as a predictor of the degree of joint destruction during the six months after measurement in patients with early rheumatoid arthritis [J]. Arthritis Rheum, 2000, 52 (4) : 852 - 858.
6Green MJ, Gough AK, Devlin J, et al. Serum MMP -3 and MMP - 1 and progression of joint damage in early rheumatoid arthritis [ J ]. Rheumatology, 2003, 42 (1): 83-88.
7Ribbens C, Andre B, Kaye O, et al. Synovial fluid matrix metalloprotei- Base -3 levels are increased in inflantraatory arthritides whether erosiveor not [J]. Rheumatology (Oxford), 2000, 39 (12) : 1357 - 1365.
8梁柳琴,许韩师,杨岫岩,叶玉津,詹钟平,陈伟玲.类风湿关节炎血清基质金属蛋白酶-3检测及其临床意义[J].中山大学学报（医学科学版）,2004,25(B06):128-131. 被引量：10
9Schenekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide [ J ]. Arthritis Rheum, 2000, 43 ( 1 ) : 155 - 163.
10赵金霞,王志敏,栗占国.以抗环瓜氨酸肽抗体改进对1987年美国风湿病学会关于类风湿关节炎分类标准的探讨[J].中华风湿病学杂志,2009,13(4):236-239. 被引量：33

二级参考文献30

1Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum, 1958, 31:315-324.
2Saraux A, Berthelot JM, Chales G, et al. Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. Arthritis Rheum, 2001, 44: 2485-2491.
3Zendman A J, Vossenaar ER, van Venrooij WJ. Autoantibodies to citrullinated (poly) peptides: a key diagnostic and prognostic marker for rheumatoid arthritis. Autoimmunity, 2004, 37: 295-299.
4Liao KP, Batra KL, Chibnik L, et al. Anti-CCP revised criteria for the classification of rheumatoid arthritis. Ann Rheum Dis, 2008, 67: 1557-1561.
5Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum, 1996, 39: 713-722.
6Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum, 2002, 46: 328-346.
7Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease -modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum, 2008, 59: 762-784.
8Kaarela K, Kauppi MJ, Lehtinen KE. The value of the ACR 1987 criteria in very early rheumatoid arthritis. Stand J Rheumatol, 1995, 24: 279-281.
9Aletaha D, Breedveld FC, Smolen JS. The need for new classification criteria for rheumatoid arthritis. Arthritis Rheum, 2005, 52:3333-3336.
10Visser H, le Cessie S, Vos K, et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum, 2002, 46: 357-365.